EchoIQ Limited (ASX:EIQ) has been one of the more talked-about names in ASX health technology through 2026, and its shares have seen the kind of sharp two-way swings common to fast-moving MedTech stocks. The company develops AI-powered cardiac diagnostic software aimed at improving the detection of serious heart conditions. After a strong run driven by US progress and Partnership news, EIQ has continued to feature among actively traded ASX shares in September 2026 as investors weigh its commercial momentum against lofty expectations.

Latest Developments

EchoIQ's flagship product, EchoSolv, applies artificial intelligence to echocardiogram data to help clinicians identify conditions such as severe aortic stenosis and other structural heart disease earlier. The company has advanced its US strategy on the back of FDA clearance for its technology and has highlighted a partnership pathway involving imaging group Pro Medicus.

In 2026 EchoIQ released its full-year financial statements and annual report, hosted investor updates on its AI-driven cardiology strategy, and reported progress including research collaborations and hospital engagements. The company has positioned itself as a funded Business scaling EchoSolv into the large US healthcare market.

Among the developments highlighted during the year were a research collaboration to evaluate AI-driven cardiac risk stratification in cancer patients and continued emphasis on its partnership pathway with Pro Medicus, a well-regarded imaging technology group. EchoIQ has also referenced teaching-hospital engagement as part of building clinical credibility and reference sites in the United States, which it views as important for wider commercial rollout.

What Could Come Next

Near-term catalysts include further US hospital and health-system deployments, progress under the Pro Medicus partnership, outcomes from research collaborations, and any commercial contracts that demonstrate recurring revenue. Updates on reimbursement and adoption pace would also be closely watched. Material developments would be disclosed via ASX announcements and investor updates.

Risks to Watch

EchoIQ faces the risks typical of scaling medtech companies. US hospital sales cycles are long, and adoption may take longer than the market anticipates. The company may need further Capital as it grows. Competition in cardiac AI is increasing. The shares have shown high Volatility and can move sharply on single announcements, meaning sentiment can reverse quickly. Execution against elevated expectations is the central challenge.

Conclusion

EchoIQ Limited (ASX:EIQ) combines a clear clinical rationale, FDA clearance and a notable partnership pathway as it pushes EchoSolv into the US market. The stock's volatility reflects the high hopes attached to that opportunity. The key question for investors is whether EchoIQ can convert clearances, collaborations and pilots into scalable, recurring revenue. Upcoming commercial and partnership updates in late 2026 are likely to be decisive for sentiment.